Background
Our previous research suggested the involvement γ-aminobutyric acid (GABA), in particular the GABAB receptor subtype, in the interoceptive effects of Δ9-tetrahydrocannabinol (Δ9-THC). The aim of the present study was to determine the potential involvement of the GABAA receptor subtype by assessing the separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ9-THC using pharmacologically selective drug-discrimination procedures.
Methods
Ten cannabis users learned to discriminate 30 mg oral Δ9-THC from placebo and then received diazepam (5 and 10 mg), Δ9-THC (5, 15 and 30 mg) and placebo, alone and in combination. Self-report, task performance and physiological measures were also collected.
Results
Δ9-THC functioned as a discriminative stimulus, produced subjective effects typically associated with cannabinoids (e.g., High, Stoned, Like Drug) and elevated heart rate. Diazepam alone impaired performance on psychomotor performance tasks and increased ratings on a limited number of self-report questionnaire items (e.g., Any Effect, Sedated), but did not substitute for the Δ9-THC discriminative stimulus or alter the Δ9-THC discrimination dose-response function. Similarly, diazepam had limited impact on the other behavioral effects of Δ9-THC.
Conclusions
These results suggest that the GABAA receptor subtype has minimal involvement in the interoceptive effects of Δ9-THC, and by extension cannabis, in humans.